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To develop evidence-based international consensus recommen-
dations for the management of hip and knee osteoarthritis (OA).
Sixteen experts from 4 medical disciplines (primary care,
rheumatology, orthopaedics and evidence based medicine), 2
continents and 6 countries (USA, UK, France, Netherlands, Swe-
den and Canada) formed the guidelines development team. A
systematic review of existing guidelines for the management of
hip and knee OA published between 1945 and January 2006 was
undertaken using the validated AGREE instrument. The core
management modalities were generated based on the agree-
ment between guidelines. Evidence before 2002 was based on a
systematic review conducted by EULAR and evidence after 2002
was updated using MEDLINE, EMBASE, CINAHL, AMED, the
Cochrane Library and HTA reports. The quality of evidence was
evaluated, and where possible, effect size (ES), number needed
to treat (NNT), relative risk (RR) or odds ratio (OR) and cost
per quality adjusted life years (QALY) gained were estimated.
Consensus recommendations were produced following a Delphi
exercise and the strength of recommendation for propositions re-
lating to each modality was determined using a visual analogue
scale (VAS).
Twenty-three treatment guidelines for the management of hip
and knee OA were identiﬁed from the literature search, including
6 opinion-based (mean quality score 28%), 5 evidence-based
(41%) and 12 based on both expert opinion and research evi-
dence (51%) (p=0.001). Fifty-one different treatment modalities
were addressed by these guidelines, but only 20 were universally
recommended. Effect size (ES) for pain relief varied from treat-
ment to treatment. Overall there was no statistically signiﬁcant
difference between non-pharmacological therapies (ES=0.25,
95%CI 0.16, 0.34) and pharmacological therapies (ES=0.39,
95%CI 0.31, 0.47). Following six Delphi rounds and feedback
from OARSI members on the draft recommendations, twenty-
ﬁve recommendations, spanning non-pharmacological, pharma-
cological and surgical therapies were agreed. Strengths of rec-
ommendation and 95% conﬁdence intervals were provided.
Twenty-ﬁve recommendations were generated based on the criti-
cal appraisal of existing guidelines, systematic review of research
evidence and expert consensus. The recommendations may be
adapted for use in different countries or regions according to the
availability of treatment modalities and strength of recommenda-
tion for each modality of therapy. These recommendations will
be revised regularly following systematic review of new research
evidence as this becomes available.
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Purpose: Numerous animal models of osteoarthritis (OA) are uti-
lized by industry and academia for evaluating potential DMOADs
as well as understanding the pathophysiology of the disease.
The choice of species and mode of OA induction are dependent
upon a number of factors.
Methods: The selection of the species to be used depends
on the type of study to be performed: e.g. KO studies are re-
stricted to mice and gene proﬁling studies may be better suited
to larger animals (dogs, rabbits) in order to be able to col-
lect sufﬁcient quantities of cartilage with no contamination of
underlying bone. For the evaluation of potential DMOADs, the
method of administration and expertise in those techniques for
that species needs to be taken into account, along with com-
pound mechanism, species difference, compound availability,
metabolism and pharmacokinetics. Most OA studies are long-
term (weeks to months) and require substantial amounts of
compound to be synthesized. This in itself can make rodent
models vastly more attractive. Certain situations preclude the
use of some species. For example, a compound developed
for interaction with a human target may not be active in other
species, particularly rodents. Under these conditions, an alter-
nate model in a higher species such as dog or monkey, which
better mimic the human, should be sought. Where all the can-
didate animals differ from the human, a transgenic animal may
be created which has the human sequence, for drug-screening
purposes.
Results: The choice of OA induction, whether spontaneous,
surgical or enzymatic, depends upon the question being asked
as well as on the historic experience of the investigators. While
spontaneous OA resembles the slowly developing nature of hu-
man OA in some regards, the unknown etiology of OA in many
spontaneous models makes it challenging to obtain robust ef-
ﬁcacy. The different sourcing of a similar strain (e.g. STR/ort)
following 10 generations of breeding results in a distinct line
so that the results may be quite dissimilar. In general, the long
duration of spontaneous models requires substantial quantities
of compound. The surgical models can vary vastly in the severity
and location of the OA lesions induced. In general, we observe
that models that are more severe (e.g. ACLT in mice) result in
maximal biomechanical damage to the joint that can be chal-
lenging to ameliorate with pharmacological treatment. Therefore,
a model with more moderate progression of OA over time may
be preferred. The enzymatic models (e.g. IA collagenase in
mice) can also result in severe erosion to the cartilage, which
resembles the ACLT model in the severe erosion of the posterior
plateau to the growth plate in a signiﬁcant proportion of animals.
Conclusions: Since there is no DMOAD in the clinic, no animal
model has been validated to be predictive of human OA. Until
this situation is rectiﬁed, the evaluation of multiple models tai-
lored to the speciﬁcs of the study and target is recommended.
In this session we will discuss various rodent and non-rodent
OA models and highlight the advantages and disadvantages of
various models with speciﬁc examples where available.
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Purpose: To highlight the challenges of randomized controlled
trials of surgical interventions and to suggest approaches for
meeting these challenges.
Methods: This workshop will address key methodological ques-
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tions regarding surgical RCT’s in a lively format that will draw
examples several recently published or ongoing surgical trials.
Results: The randomized controlled trial (RCT) is the time-
honored scientiﬁc approach for assessing the efﬁcacy of inter-
ventions. Trial methodology has developed largely to conform to
the needs of pharmacologic studies. When RCTs are performed
in other settings, such as to assess the efﬁcacy of a surgical
intervention, investigators must confront difﬁcult methodological
questions. Some of these are unique to the non-pharmacological
setting and others are more challenging in this setting. For ex-
ample: what is an appropriate control in a trial of a surgical
intervention? Is sham surgery ethically defensible? To what ex-
tent can blinding can be achieved in the absence of a sham?
How does the research team ensure and assess compliance
with surgical or non surgical intervention? What are the scien-
tiﬁc consequences of cross-overs (from nonoperative therapy to
surgery, and vice versa) ? How can cross-overs be minimized
in the design of trials and accounted for in the trial analysis?
How should the investigator account for the effects of correlation
among patients of the same surgeon and the same hospital in
the design and analysis of trials?
Conclusions: This workshop will be of particular interest to
persons interested in non-pharmacological trials in OA, including
trials of surgery.
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The ongoing challenge of identifying valid molecular biomarkers
to monitor osteoarthritis (OA) has involved translating basic stud-
ies of joint tissue metabolism into reliable biochemical assays of
accessible body ﬂuid samples (i.e. synovial ﬂuid, serum, plasma,
urine) [1]. Predominantly, the aim of such assays is to survey the
turnover/release of macromolecules which may originate from
affected articular tissues (such as cartilage), and correlate these
levels with the degree of disease activity.
Practicable assays have been reported (and in many cases are
commercially available) for, among others, aggrecan degradation
products and substituents (i.e. glycosaminoglycans), type II col-
lagen fragments, cartilage oligomeric matrix protein (COMP) and
hyaluronan (HA). In addition, procedures to assay the neosynthe-
sis of aggrecan and collagens are described, and offer additional
measurements for combining multiple biomarker parameters in
attempts to enhance diagnostic accuracy [2-4].
Attention has also been directed toward the catabolism of small
leucine-rich proteoglycans (SLRPs) and the ability to quantify
relevant SLRP fragments in biomarker assays [5]. Other logical
candidates to assess may include the cartilage boundary glyco-
protein lubricin/PRG4 [6], and a variety of other proteinaceous
components which, for example, are differentially abundant in
normal and osteoarthritic human cartilage extracts [7].
While inherent variation among individuals poses signiﬁcant hur-
dles, the utility of using appropriate molecular biomarkers as
surrogate measures of OA offers promise for longitudinal as-
sessments, and in the evaluation of potential responses to ther-
apeutic, interventional treatments [8].
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BIOLOGY & BIOMECHANICS OF AGING JOINTS –
ROLES IN OSTEOARTHRITIS
J. Buckwalter, J. Martin
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Purpose: A number of factors increase the risk of osteoarthritis
including genetic predisposition, body mass, and developmental
disorders including joint dysplasias. However, in all populations,
age and excessive articular surface contact stress are asso-
ciated with substantial increases in the probability of the joint
degeneration that leads to the clinical syndrome of osteoarthritis.
With increasing age, articular cartilage loses tensile stiffness and
strength, frequently develops superﬁcial ﬁbrillation and alteration
of matrix macromolecules including proteoglycans and collagens.
We have been investigating the causes of these biological and
biomechanical age related changes in articular cartilage.
Methods: To examine the age related changes in human chon-
drocytes we have harvested articular cartilage samples from
humans ranging in age from newborns to the elderly. We have
studied the function of the chondrocytes in culture and in their
native matrix and tested their responses to mechanical stimuli
and antioxidants.
Results: We have found that with increasing age human chon-
drocytes show decreased synthetic activity, decreased prolifer-
ative activity, altered proteoglycan synthesis and a decline in
the response to anabolic growth factors. In addition, we have
found that with increasing age chondrocytes show a decline
in cartilage speciﬁc gene expression including aggrecan gene
expression and in their ability to form a cartilaginous matrix in
culture. In human chondrocytes these changes are associated
with a decrease in telomere length. Recent studies indicate that
loss of telomere length is a marker of impaired chondrocyte
function that is caused at least in part by cumulative oxidative
damage. We have also explored the role of chondrocyte ox-
idative damage in the development of osteoarthritis in young
adults and in particular the osteoarthritis that develops follow-
ing joint injuries (post-traumatic osteoarthritis) and in association
with joint dysplasia. In both of these conditions the articular sur-
face is exposed to increased contact stress. A study of human
articular cartilage in vitro shows that increased contact stress
and in particular shear stress increases the release the oxygen
free radicals. This increase in oxygen free radicals is associated
with chondrocyte death and apoptosis and use of antioxidants
blocks a substantial fraction of this deleterious effect. In addition,
we have found that pre-conditioning chondrocytes with oxidants
appears to stimulate antioxidant defenses and protects the cells
from mechanical stress induced apoptosis and death. Protect-
ing human chondrocytes from oxidative damage and providing
them with telomerase as a DNA repair mechanism substantially
